879 related articles for article (PubMed ID: 32483459)
1. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale Copper(II)-Diethyldithiocarbamate Coordination Polymer as a Drug Self-Delivery System for Highly Robust and Specific Cancer Therapy.
Peng Y; Liu P; Meng Y; Hu S; Ding J; Zhou W
Mol Pharm; 2020 Aug; 17(8):2864-2873. PubMed ID: 32551674
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of nanoparticle and molecular drug by hollow mesoporous organosilica for tumor-activated and photothermal-augmented chemotherapy of breast cancer.
Zhang H; Song F; Dong C; Yu L; Chang C; Chen Y
J Nanobiotechnology; 2021 Sep; 19(1):290. PubMed ID: 34579711
[TBL] [Abstract][Full Text] [Related]
4. Copper(II)-disulfiram loaded melanin-dots for cancer theranostics.
Shi H; Suo Y; Zhang Z; Liu R; Liu H; Cheng Z
Nanomedicine; 2021 Feb; 32():102340. PubMed ID: 33227540
[TBL] [Abstract][Full Text] [Related]
5. Dual Action of Acidic Microenvironment on the Enrichment of the Active Metabolite of Disulfiram in Tumor Tissues.
Tang C; Pang X; Guo Z; Guo R; Liu L; Chen X
Drug Metab Dispos; 2021 Jun; 49(6):434-441. PubMed ID: 33762296
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy.
Li Q; Chao Y; Liu B; Xiao Z; Yang Z; Wu Y; Liu Z
Biomaterials; 2022 Dec; 291():121880. PubMed ID: 36334355
[TBL] [Abstract][Full Text] [Related]
7. Copper-Enriched Prussian Blue Nanomedicine for In Situ Disulfiram Toxification and Photothermal Antitumor Amplification.
Wu W; Yu L; Pu Y; Yao H; Chen Y; Shi J
Adv Mater; 2020 Apr; 32(17):e2000542. PubMed ID: 32162734
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Tumor-Specific Disulfiram Chemotherapy by
Wu W; Yu L; Jiang Q; Huo M; Lin H; Wang L; Chen Y; Shi J
J Am Chem Soc; 2019 Jul; 141(29):11531-11539. PubMed ID: 31251050
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers.
Chen W; Yang W; Chen P; Huang Y; Li F
ACS Appl Mater Interfaces; 2018 Dec; 10(48):41118-41128. PubMed ID: 30444340
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
11. Surface Decoration via Physical Interaction of Cupric Diethyldithiocarbamate Nanocrystals and Its Impact on Biodistribution and Tumor Targeting.
Meng Z; Wang H; Fang X; Liu Z; Yang Z; Yong J; Yang Q; Bai Y; Ren H; Xu H; Li X
ACS Appl Mater Interfaces; 2021 Aug; 13(31):36894-36908. PubMed ID: 34328715
[TBL] [Abstract][Full Text] [Related]
12. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.
Buchtova T; Skrott Z; Chroma K; Rehulka J; Dzubak P; Hajduch M; Lukac D; Arampatzis S; Bartek J; Mistrik M
Mol Oncol; 2022 Apr; 16(7):1541-1554. PubMed ID: 34632694
[TBL] [Abstract][Full Text] [Related]
14. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicine Enables Drug-Potency Activation with Tumor Sensitivity and Hyperthermia Synergy in the Second Near-Infrared Biowindow.
Liu W; Xiang H; Tan M; Chen Q; Jiang Q; Yang L; Cao Y; Wang Z; Ran H; Chen Y
ACS Nano; 2021 Apr; 15(4):6457-6470. PubMed ID: 33750100
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the accumulation of disulfiram and its copper complex in A549 cells using mass spectrometry.
Lu X; Lin B; Xu N; Huang H; Wang Y; Lin JM
Talanta; 2020 May; 211():120732. PubMed ID: 32070566
[TBL] [Abstract][Full Text] [Related]
17. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D; Skrott Z; Bouchal J; Bartkova J; Simkova D; Gachechiladze M; Steigerova J; Kurfurstova D; Gursky J; Korinkova G; Cwiertka K; Hodny Z; Mistrik M; Bartek J
Prostate; 2019 Mar; 79(4):352-362. PubMed ID: 30499118
[TBL] [Abstract][Full Text] [Related]
18. Photothermally Triggered Copper Payload Release for Cuproptosis-Promoted Cancer Synergistic Therapy.
Zhou J; Yu Q; Song J; Li S; Li XL; Kang BK; Chen HY; Xu JJ
Angew Chem Int Ed Engl; 2023 Mar; 62(12):e202213922. PubMed ID: 36585379
[TBL] [Abstract][Full Text] [Related]
19. Buffet-style Cu(II) for enhance disulfiram-based cancer therapy.
Zhao L; Wang X; Lou H; Jiang M; Wu X; Qin J; Zhang J; Guan X; Li W; Zhang W; Ma J
J Colloid Interface Sci; 2022 Oct; 624():734-746. PubMed ID: 35696791
[TBL] [Abstract][Full Text] [Related]
20. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X; Jadhav S; Annaji M; Huang CH; Amin R; Shen J; Ashby CR; Tiwari AK; Babu RJ; Chen P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
